Hilleman Laboratories, a joint venture between pharma company MSD and Wellcome Trust, on Monday said Raman Rao will assume the role of its chief executive officer on February 1, 2020.
He will replace Davinder Gill who will leave as CEO of the company on January 31, 2020, Hilleman Laboratories said in a statement.
Rao has more than 22 years' experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases, and is joining from Takeda Vaccines where he was Vice President of Global Product Operations, it added.
Established in 2009, Hilleman Laboratories is a research and development joint venture with a not-for-profit mission to develop affordable vaccines for diseases that commonly affect low-income countries.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app